Clareo Health | A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin
A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult patients \>/=18 years of age
metastatic colorectal cancer
at least 1 measurable lesion according to RECIST v. 1.1
patients with disease progression with prior FOLFIRI + Avastin therapy who are not candidates for primary metastasectomy
disease progression \</= 8 weeks after last dose of Avastin
ECOG \</=2
No more than 8 weeks between 1st-line treatment with FOLFIRI + Avastin and 2nd-line treatment with XELOX or FOLFOX + Avastin
You may not be if
disease progression \> 8 weeks after last Avastin administration
clinically significant cardiovascular disease
CNS disease except for treated brain metastasis
history of other malignancies within 2 years prior to start of study treatment (with the exception of curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix)
major surgery, open biopsy, or significant traumatic injury within 28 days prior to start of study treatment
